Syenza’s News Roundup: Launching a New Era of Healthcare Insights

By HEOR Staff Writer

September 7, 2023

We are excited to announce the launch of our new newsletter, “Value Science Weekly”. This weekly digest is designed to keep you up-to-date on the latest trends, insights, and breakthroughs in Health Economics and Outcomes Research (HEOR), Global Market Access, and Dynamic Intelligence.

In our next week’s issue, we delve into the transformative potential of virtual care in neurology, as highlighted by the World Health Organization. The rising demand for continuous home and institutional care, driven by an ageing population and increasing prevalence of chronic diseases, is being met head-on by advancements in virtual care. Our rapid insight article explores how virtual care is reshaping patient evaluation, treatment, and follow-up, particularly in the field of neurology.

But that’s just the beginning. Each week, our newsletter will bring you expert perspectives and thought-provoking analyses from renowned researchers and industry leaders. You’ll also discover the latest studies and real-world evidence shaping the economic value and patient outcomes of healthcare interventions. Plus, we’ll keep you informed about policy changes, regulatory updates, and reimbursement frameworks that could impact your work.

We’re also excited to share innovations in market access and healthcare delivery, showcasing the cutting-edge technologies and transformative approaches that are emerging in our industry.

Don’t miss out on these valuable insights. Subscribe to “Value Science Weekly” today for your weekly dose of healthcare innovation news. We look forward to embarking on this journey with you.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy
Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...